These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36344076)

  • 1. Non-Modulator Therapies: Developing a Therapy for Every Cystic Fibrosis Patient.
    Egan ME
    Clin Chest Med; 2022 Dec; 43(4):717-725. PubMed ID: 36344076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.
    Egan ME
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome Editing for Cystic Fibrosis.
    Wang G
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.
    Clarke LA; Awatade NT; Felício VM; Silva IA; Calucho M; Pereira L; Azevedo P; Cavaco J; Barreto C; Bertuzzo C; Gartner S; Beekman J; Amaral MD
    Hum Mutat; 2019 Mar; 40(3):326-334. PubMed ID: 30488522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy in cystic fibrosis.
    Prickett M; Jain M
    Transl Res; 2013 Apr; 161(4):255-64. PubMed ID: 23273902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New horizons for cystic fibrosis treatment.
    Fajac I; De Boeck K
    Pharmacol Ther; 2017 Feb; 170():205-211. PubMed ID: 27916649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
    Carbone A; Vitullo P; Di Gioia S; Conese M
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
    Schneider-Futschik EK
    Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.
    Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
    Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging gene therapies for cystic fibrosis.
    Miah KM; Hyde SC; Gill DR
    Expert Rev Respir Med; 2019 Aug; 13(8):709-725. PubMed ID: 31215818
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic therapies in cystic fibrosis.
    Taylor-Cousar JL; Boyd AC; Alton EWFW; Polineni D
    Curr Opin Pulm Med; 2023 Nov; 29(6):615-620. PubMed ID: 37700667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging medicines to improve the basic defect in cystic fibrosis.
    Fajac I; Sermet-Gaudelus I
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFTR modulator theratyping: Current status, gaps and future directions.
    Clancy JP; Cotton CU; Donaldson SH; Solomon GM; VanDevanter DR; Boyle MP; Gentzsch M; Nick JA; Illek B; Wallenburg JC; Sorscher EJ; Amaral MD; Beekman JM; Naren AP; Bridges RJ; Thomas PJ; Cutting G; Rowe S; Durmowicz AG; Mense M; Boeck KD; Skach W; Penland C; Joseloff E; Bihler H; Mahoney J; Borowitz D; Tuggle KL
    J Cyst Fibros; 2019 Jan; 18(1):22-34. PubMed ID: 29934203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.
    McHugh DR; Steele MS; Valerio DM; Miron A; Mann RJ; LePage DF; Conlon RA; Cotton CU; Drumm ML; Hodges CA
    PLoS One; 2018; 13(6):e0199573. PubMed ID: 29924856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.
    Kim YJ; Krainer AR
    Mol Cells; 2023 Jan; 46(1):10-20. PubMed ID: 36697233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.